Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study

BACKGROUND: Nintedanib in combination with docetaxel is approved in the European Union and other countries for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy, based on the overall survival findings of Phase III LUM...

Descripción completa

Detalles Bibliográficos
Autores principales: Reck, Martin, Mellemgaard, Anders, Novello, Silvia, Postmus, Pieter E, Gaschler-Markefski, Birgit, Kaiser, Rolf, Buchner, Hannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084077/
https://www.ncbi.nlm.nih.gov/pubmed/30122949
http://dx.doi.org/10.2147/OTT.S170722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084077/
https://www.ncbi.nlm.nih.gov/pubmed/30122949
http://dx.doi.org/10.2147/OTT.S170722

Ejemplares similares